Biotech News
Related news
ERASErasca2026-11-20 12:00 EST
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
ERASErasca2026-11-04 13:30 EST
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
PRLDPrelude Therapeutics2026-10-13 11:01 EST
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
BMYBMYBristol-Myers Squibb Company2026-11-19 11:59 EST
Bristol Myers Squibb Demonstrates Breadth and Clinical Momentum Across Blood Cancers and Rare Hematologic Disorders at ASH 2026
BMYBMYBristol-Myers Squibb Company2026-11-18 14:10 EST
Bristol Myers Squibb Presents First Clinical Data from Two Phase 3 Studies in the ADEPT Program Evaluating KarXT for Psychosis Associated with Alzheimer’s Disease
BNTXBioNTech2026-10-25 07:30 EST
BioNTech und Bristol Myers Squibb präsentieren ermutigende Daten aus globaler Phase-2-Studie mit Pumitamig bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs nach Progression der Erkrankung unter einer Immuntherapie und Chemotherapie
KURAKura Oncology2026-11-04 14:02 EST
Kura Oncology and Kyowa Kirin to Present First Ziftomenib-FLT3 Inhibitor Clinical Data at ASH 2026
ACRVAcrivon Therapeutics2026-10-29 12:00 EST
Acrivon Announces Late-Breaking Oral Plenary Presentation of Early Phase 1/2 Clinical Results in AP3-Predicted Tumors for its First-in-Class WEE1/PKMYT1 Inhibitor ACR-2316 at the 38th EORTC-NCI-AACR Symposium
GERNGeron2026-10-28 12:00 EST
Geron Corporation Provides Update on Phase 3 IMpactMF Clinical Trial of Imetelstat in Relapsed/Refractory Myelofibrosis
BNTXBioNTech2026-10-26 09:00 EST
BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer
Erasca
RAS/MAPK Precision Oncology Erasca is a clinical-stage precision-oncology company developing therapies for cancers driven by the RAS/MAPK pathway. Its portfolio is designed to address genetically defined tumors through direct RAS inhibition. ERAS-0015 ERAS-0015 is a pan-RAS molecular glue being evaluated in the AURORAS clinical program....
Recent company news
ERASErasca2026-11-20 12:00 EST
Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015
ERASErasca2026-11-17 23:40 EST
Erasca Enters into Clinical Collaboration with Bristol Myers Squibb to Evaluate ERAS-0015 in Clinical Study with Navlimetostat
ERASErasca2026-11-16 13:01 EST
Erasca to Host Virtual Investor Event Highlighting Clinical Momentum Across Its RAS-Targeting Franchise
ERASErasca2026-11-12 21:01 EST
Erasca Reports Third Quarter 2026 Business Updates and Financial Results
ERASErasca2026-11-04 13:30 EST
Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015
Stock data
- Close
- 14.22 USD
- Market cap
- 4.19B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
